ERBB2 and gastric cancer: Preclinical data to support this result have recently been described; however, HER2-positive patients with esophagogastric cancer have not previously been demonstrated to have inferior response rates to chemotherapy.22 In the Trastuzumab for Gastric Cancer trial, the radiologic response rate to cisplatin-fluoropyrimidine therapy was 35%, which is consistent with other similar data sets.23,24 We have also previously demonstrated that HER2 status in MAGIC was not associated with differential survival outcomes, and we believe that this result requires further verification.13